<p>Fisher Asset Management LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在诺华制药（NYSE:NVS - 免费报告）的持股增加了 5.3%。该机构投资者在此期间购买了额外的 358,282 股后，持有该公司 7,121,414 股股票。Fisher Asset Management LLC 在最近一个季度末持有诺华 0.34% 的股份，价值 861,762,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在诺华的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股该公司的股票，价值 599,000 美元，此前在上个季度又收购了 2,666 股。TD Asset Management Inc 在第一季度将其在诺华的持股增加了 8.6%。TD Asset Management Inc 目前持有 17,429 股该公司的股票，价值 1,943,000 美元，此前在上个季度又购买了 1,374 股。Commerce Bank 在第一季度将其在诺华的持股增加了 12.2%。Commerce Bank 目前持有 23,813 股该公司的股票，价值 2,655,000 美元，此前在上个季度又购买了 2,581 股。TIAA Trust National Association 在第一季度将其在诺华的持股增加了 7.6%。TIAA Trust National Association 目前持有 8,474 股该公司的股票，价值 945,000 美元，此前在上个季度又购买了 599 股。最后，IFG Advisory LLC 在第一季度将其在诺华的持股增加了 427.6%。IFG Advisory LLC 目前持有 12,869 股该公司的股票，价值 1,435,000 美元，此前在上个季度又购买了 10,430 股。目前，13.12% 的股票由机构投资者和对冲基金持有。</p>
<h2>分析师评级升级与降级</h2>
<p>几位股票分析师对 NVS 股票发布了报告。Cowen 在 11 月 10 日的研究报告中重申了对诺华股票的 “持有” 评级。Jefferies Financial Group 在 10 月 27 日的研究报告中重申了对诺华股票的 “持有” 评级。摩根士丹利在 10 月 31 日的研究报告中将诺华的评级从 “等权重” 上调至 “超配”。Cfra Research 在 10 月 29 日的报告中将诺华的评级上调至 “持有”。最后，Weiss Ratings 在周三的研究报告中重申了对诺华股票的 “买入（b）” 评级。一位投资分析师对该股票给予了强烈买入评级，四位分析师给予了买入评级，六位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 122.33 美元。</p>
<ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
<p><strong>获取我们最新的 NVS 研究报告</strong></p>
<h2>诺华股价下跌 0.2%</h2>
<p>诺华股票在周一开盘时为 130.23 美元。该公司的市值为 2750.9 亿美元，市盈率为 17.79，市盈率增长比率为 1.93，贝塔值为 0.60。该公司的流动比率为 0.88，速动比率为 0.62，债务与股本比率为 0.50。该公司的 50 日移动平均线为 128.31 美元，200 日移动平均线为 122.74 美元。诺华 AG 的 12 个月低点为 96.06 美元，12 个月高点为 134.00 美元。</p>
<ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）最近在 10 月 28 日发布了季度财报。该公司报告季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司的每股收益为 2.06 美元。诺华本季度的收入较去年同期增长了 8.5%。股票分析师预测诺华 AG 本年度每股收益将达到 8.45 美元。</p>
<h2>诺华公司简介</h2>
<p>（免费报告）</p>
<p>诺华 AG 从事医疗保健产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Klarna 的加密计划：解决其盈利问题的计划</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
<p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>Fisher Asset Management LLC 在第二季度将其在诺华制药的持股增加了 5.3%，目前持有 7,121,414 股，价值 8.6176 亿美元。其他机构投资者也增加了他们的持仓。诺华的市值为 2750.9 亿美元，市盈率为 17.79。分析师对该股票的评级不一，平均目标价为 122.33 美元。诺华报告第三季度每股收益为 2.25 美元，略低于预期，营收同比增长 8.5%</p>

<p>Fisher Asset Management LLC increased its position in shares of Novartis AG (NYSE:NVS - Free Report) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,121,414 shares of the company's stock after purchasing an additional 358,282 shares during the period. Fisher Asset Management LLC owned 0.34% of Novartis worth $861,762,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Fisher Asset Management LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在诺华制药（NYSE:NVS - 免费报告）的持股增加了 5.3%。该机构投资者在此期间购买了额外的 358,282 股后，持有该公司 7,121,414 股股票。Fisher Asset Management LLC 在最近一个季度末持有诺华 0.34% 的股份，价值 861,762,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after acquiring an additional 2,666 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Novartis by 8.6% during the 1st quarter. TD Asset Management Inc now owns 17,429 shares of the company's stock worth $1,943,000 after buying an additional 1,374 shares during the last quarter. Commerce Bank boosted its holdings in shares of Novartis by 12.2% in the 1st quarter. Commerce Bank now owns 23,813 shares of the company's stock valued at $2,655,000 after buying an additional 2,581 shares in the last quarter. TIAA Trust National Association boosted its holdings in shares of Novartis by 7.6% in the 1st quarter. TIAA Trust National Association now owns 8,474 shares of the company's stock valued at $945,000 after buying an additional 599 shares in the last quarter. Finally, IFG Advisory LLC grew its position in shares of Novartis by 427.6% in the 1st quarter. IFG Advisory LLC now owns 12,869 shares of the company's stock valued at $1,435,000 after buying an additional 10,430 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也买卖了该公司的股票。Brighton Jones LLC 在第四季度将其在诺华的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股该公司的股票，价值 599,000 美元，此前在上个季度又收购了 2,666 股。TD Asset Management Inc 在第一季度将其在诺华的持股增加了 8.6%。TD Asset Management Inc 目前持有 17,429 股该公司的股票，价值 1,943,000 美元，此前在上个季度又购买了 1,374 股。Commerce Bank 在第一季度将其在诺华的持股增加了 12.2%。Commerce Bank 目前持有 23,813 股该公司的股票，价值 2,655,000 美元，此前在上个季度又购买了 2,581 股。TIAA Trust National Association 在第一季度将其在诺华的持股增加了 7.6%。TIAA Trust National Association 目前持有 8,474 股该公司的股票，价值 945,000 美元，此前在上个季度又购买了 599 股。最后，IFG Advisory LLC 在第一季度将其在诺华的持股增加了 427.6%。IFG Advisory LLC 目前持有 12,869 股该公司的股票，价值 1,435,000 美元，此前在上个季度又购买了 10,430 股。目前，13.12% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>Several equities analysts have issued reports on NVS shares. Cowen restated a &#34;hold&#34; rating on shares of Novartis in a research note on Monday, November 10th. Jefferies Financial Group restated a &#34;hold&#34; rating on shares of Novartis in a research note on Monday, October 27th. Morgan Stanley raised Novartis from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, October 31st. Cfra Research raised Novartis to a &#34;hold&#34; rating in a report on Wednesday, October 29th. Finally, Weiss Ratings restated a &#34;buy (b)&#34; rating on shares of Novartis in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $122.33.</p>
<div class="lb-trans"><p>几位股票分析师对 NVS 股票发布了报告。Cowen 在 11 月 10 日的研究报告中重申了对诺华股票的 “持有” 评级。Jefferies Financial Group 在 10 月 27 日的研究报告中重申了对诺华股票的 “持有” 评级。摩根士丹利在 10 月 31 日的研究报告中将诺华的评级从 “等权重” 上调至 “超配”。Cfra Research 在 10 月 29 日的报告中将诺华的评级上调至 “持有”。最后，Weiss Ratings 在周三的研究报告中重申了对诺华股票的 “买入（b）” 评级。一位投资分析师对该股票给予了强烈买入评级，四位分析师给予了买入评级，六位分析师给予了持有评级，三位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价格为 122.33 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
</div><p><strong>Get Our Latest Research Report on NVS</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 NVS 研究报告</strong></p>
</div><h2>Novartis Trading Down 0.2%</h2>
<div class="lb-trans"><h2>诺华股价下跌 0.2%</h2>
</div><p>Shares of NVS stock opened at $130.23 on Monday. The company has a market capitalization of $275.09 billion, a P/E ratio of 17.79, a price-to-earnings-growth ratio of 1.93 and a beta of 0.60. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. The business's 50 day moving average is $128.31 and its two-hundred day moving average is $122.74. Novartis AG has a twelve month low of $96.06 and a twelve month high of $134.00.</p>
<div class="lb-trans"><p>诺华股票在周一开盘时为 130.23 美元。该公司的市值为 2750.9 亿美元，市盈率为 17.79，市盈率增长比率为 1.93，贝塔值为 0.60。该公司的流动比率为 0.88，速动比率为 0.62，债务与股本比率为 0.50。该公司的 50 日移动平均线为 128.31 美元，200 日移动平均线为 122.74 美元。诺华 AG 的 12 个月低点为 96.06 美元，12 个月高点为 134.00 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.25 earnings per share for the quarter, missing the consensus estimate of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The company had revenue of $14.36 billion for the quarter, compared to analyst estimates of $13.70 billion. During the same period in the prior year, the business earned $2.06 earnings per share. Novartis's revenue for the quarter was up 8.5% compared to the same quarter last year. Equities analysts forecast that Novartis AG will post 8.45 EPS for the current year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）最近在 10 月 28 日发布了季度财报。该公司报告季度每股收益为 2.25 美元，低于市场共识预期的 2.26 美元（差额为 0.01 美元）。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 143.6 亿美元，而分析师预期为 137 亿美元。在去年同期，该公司的每股收益为 2.06 美元。诺华本季度的收入较去年同期增长了 8.5%。股票分析师预测诺华 AG 本年度每股收益将达到 8.45 美元。</p>
</div><h2>Novartis Company Profile</h2>
<div class="lb-trans"><h2>诺华公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华 AG 从事医疗保健产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其重点领域包括心血管、肾脏和代谢、免疫学、神经科学和肿瘤学，以及眼科和血液学。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Worried About Inflation? These 3 ETFs Offer Real Protection</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Klarna's Crypto Play: A Plan to Fix Its Profit Problem</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>什么是稀释每股收益（Diluted EPS）？</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
<li>股息筛选器：如何在购买前评估股息股票</li>
<li>Klarna 的加密计划：解决其盈利问题的计划</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

诺华制药 $NVS 股票被 Fisher Asset Management LLC 收购